Lux Research Release: Previewing Health and Wellness in a Post-Pharma World
5/17/2011 9:40:58 AM
BOSTON--(BUSINESS WIRE)--The large drugmakers that have epitomized health for a century are in terminal decline, having adhered too long to a blockbuster-drug model that is now failing catastrophically. Today, firms like AstraZeneca and Pfizer face a $143 billion patent cliff and have run out of room for organic growth, forcing them to consolidate rapidly. But this hardly means the end of medicine – on the contrary, conventional medicine’s collapse is opening up new spaces for more personalized, humane, affordable, and effective healthcare. In its latest report, Lux Research explains how today’s partnerships show where tomorrow’s growth will come from: new entrants that offer better formats for delivering inexpensive, generic drugs; foods and personal care products that help manage chronic disease; and agricultural and industrial technologies that improve human and environmental health.
comments powered by